Healthcare Global Enterprises
720.00
+3.45(+0.48%)
Market Cap₹10,152.01 Cr
PE Ratio-
Company Performance:
1D+0.48%
1M-4.67%
6M+30.77%
1Y+42.55%
5Y+381.93%
View Company Insightsright
More news about Healthcare Global Enterprises
12Nov 25
HCG Enterprises Reports Q2 FY2026 Results, Approves Employee Stock Option Allotment
Healthcare Global Enterprises Limited (HCG) announced Q2 FY2026 results with revenue up 16.8% to ₹64,516 lakhs, but profit before tax down 28.3% to ₹1,982 lakhs. The company approved allotment of 7,537 equity shares under ESOP and investment of up to ₹700 lakhs in Cancer Care Kenya Limited. Board meeting held on November 12, 2025, approved unaudited financial results. BSR & Co. LLP conducted limited review with unmodified opinion.
12Nov 25
HealthCare Global Enterprises Approves Investment in Cancer Care Kenya and Outlines Multi-Year Growth Strategy
Healthcare Global Enterprises (HCG) has approved an investment of up to Rs. 700 lakhs in Cancer Care Kenya Limited, a step-down subsidiary. This strategic move aims to expand HCG's footprint in the African healthcare market. Cancer Care Kenya, operating in Nairobi, provides radiation and chemotherapy services. The company has shown significant growth, with revenue increasing from INR 90.73 crore in FY 2020-21 to INR 425.31 crore in FY 2022-23. The investment is subject to regulatory approvals and is part of HCG's multi-year growth strategy, which includes oncology expansion, clinical excellence, and leveraging digital health platforms.
04Nov 25
Motilal Oswal Mutual Fund Increases Stake in HealthCare Global Enterprises
Multiple schemes of Motilal Oswal Mutual Fund have increased their collective stake in Healthcare Global Enterprises Ltd from 4.93% to 5.04%. The fund acquired an additional 1,54,556 shares through market transactions on October 29, 2025, bringing their total holding to 71,06,458 shares. This acquisition was reported under SEBI substantial acquisition regulations and involved 11 different Motilal Oswal Mutual Fund schemes.
13Sept 25
Aceso Company Sells 5.65% Stake in HealthCare Global Enterprises
Aceso Company Pte. Ltd. has sold 79,66,310 equity shares (5.65%) of Healthcare Global Enterprises Limited (HCG) through on-market transactions. The sale occurred over two days, reducing Aceso's holding from 5.72% to 0.006%. HCG also announced the allotment of 15,84,730 equity shares under its Employee Stock Option Schemes and appointed Mr. Gopi Lama as Head of Domestic Sales.
12Sept 25
HealthCare Global Enterprises Appoints Gopi Lama as Head of Domestic Sales
Healthcare Global Enterprises Limited (HCG) has appointed Mr. Gopi Lama as the new Head of Domestic Sales, effective September 15, 2025. The Board of Directors approved the appointment based on the Nomination and Remuneration Committee's recommendation. Mr. Lama brings over 30 years of healthcare experience, including 13 years in hospital operations. He has previously worked with major healthcare organizations like Apollo, Fortis, and Narayana Health. His achievements include driving cluster revenues beyond INR 700.00 crore and expertise in sales operations and brand strategy.
11Sept 25
Morgan Stanley, Nippon India MF Lead Rs 438 Crore Share Purchase in HealthCare Global
Morgan Stanley, Nippon India Mutual Fund, Motilal Oswal MF, and Plutus Wealth Management collectively purchased 63 lakh equity shares (4.52% stake) of Healthcare Global Enterprises (HCG) for Rs 438.00 crore. The shares were priced at Rs 695.00 each on the National Stock Exchange. CVC Capital Partners' affiliate, Aceso Company Pte Ltd, was the seller, reducing its holding from 8.76% to 4.24%. This transaction follows KKR's recent agreement to acquire up to 54% stake in HCG from CVC Capital Partners for approximately USD 400 million.
10Sept 25
Aceso Company Offloads 6% Stake in HealthCare Global for ₹552 Crore
Aceso Company, part of the CVC Network, sold nearly 6% stake in Healthcare Global Enterprises (HCG) through a block deal on NSE, valued at ₹552.00 crore at ₹695.00 per share. Key buyers included Nippon India Mutual Fund, Plutus Wealth Management, Axis Mutual Fund, and Morgan Stanley Asia Singapore. This follows CVC Capital's earlier exit, reducing Aceso's stake from 60.4% to 8.8%. HCG shares have rallied 42% year-to-date, outperforming the NSE 500 index. The company reported a net profit of ₹44.00 crore on revenues of ₹2,223.00 crore in its latest results. Analysts maintain a positive outlook, with Ambit Capital setting a 12-month target price of ₹860.00.
22Aug 25
HCG Eyes 20% Margin Target as KKR Acquires Majority Stake; Promoter Reduces Shareholding
Healthcare Global Enterprises (HCG) aims to achieve a 20% margin target by the last quarter of the current financial year. The company reported 15% growth and is expanding through a hub-and-spoke model. KKR has acquired a 44-54% stake in HCG from CVC Asia V in a $400 million deal, reshaping the ownership structure. HCG recently acquired MG Hospital in Vijayawada and is now in a consolidation phase. The company's market cap stands at ₹9,386.00 crore, with shares trading at ₹672.95, gaining 73% over the past year. Promoter Dr. B.S. Ajaikumar has sold 13,92,000 equity shares, reducing his stake from 6.84% to 5.84%.
12Aug 25
HealthCare Global Enterprises Shareholders Approve Board Changes and New Articles of Association
Healthcare Global Enterprises Limited (HCG) shareholders approved several key resolutions via postal ballot. Changes include appointing Dr. B.S. Ajaikumar as Non-Executive Director and Chairman, adding new Non-Executive and Executive Directors, and appointing an Independent Director. Shareholders also approved amended Articles of Association and consultancy agreements with Dr. Ajaikumar and Mrs. Rossi. The voting saw strong participation, with most resolutions receiving over 90% approval and representing 84.93% of the company's total paid-up equity capital.
01Jul 25
Karnataka Government Calls for Probe into Alleged Unfair Clinical Trials at HCG Bengaluru
The Karnataka government has requested the Drug Controller General of India (DCGI) to investigate alleged unfair clinical trials at Healthcare Global Enterprises Ltd's (HCG) Bengaluru facility. The inquiry was prompted by concerns raised by a former chairperson of HCG's Institutional Ethics Committee regarding patient safety, regulatory compliance, and institutional integrity in clinical trials. This development could have significant implications for HCG, a prominent cancer care provider, potentially affecting its reputation and regulatory standing.
10Jun 25
Healthcare Global Enterprises Unveils Ambitious Expansion Plan
Healthcare Global Enterprises (HCG) plans to add 1,000 beds over the next three years through a hybrid expansion model. The company aims to maintain a 20% EBITDA margin despite expansion. HCG reported 18% year-on-year revenue growth but a 65% decline in Profit After Tax. The company projects 15% overall revenue growth over the next three years.
09Jun 25
Healthcare Global Targets 19-20% Profit Margins in Efficiency Drive
Healthcare Global Enterprises Ltd, a major player in the Indian healthcare sector, has announced a strategic goal to maintain profit margins between 19% and 20%. This target demonstrates the company's commitment to financial stability and operational efficiency in the face of industry challenges. The focus on sustaining these margins suggests potential initiatives in cost management, resource optimization, and service delivery improvements. This financial objective provides a clear benchmark for stakeholders and reflects the company's confidence in its business model.
26May 25
Healthcare Global Enterprises Ltd Reports Mixed Q4 Financial Results
Healthcare Global Enterprises Ltd announced Q4 results with mixed performance. Consolidated revenue increased 18.26% year-over-year to ₹5.83 billion. However, net profit declined 71.37% to ₹67 million compared to the same quarter last year. Sequential growth showed 4.67% increase in revenue but 12.99% decrease in profit from the previous quarter.
02May 25
CCI Greenlights KKR's Share Acquisition in Healthcare Global Enterprises
The Competition Commission of India (CCI) has approved a proposed share acquisition in Healthcare Global Enterprises Limited by KKR, through its entities Hector Asia Holdings and KIA EBT II Scheme. This approval allows KKR, a global investment firm, to proceed with its investment in the prominent Indian healthcare company. While specific details of the acquisition remain undisclosed, this development could potentially reshape Healthcare Global Enterprises' future operations and strategic direction.
01May 25
CCI Greenlights KKR's Acquisition of Healthcare Global Enterprises
The Competition Commission of India (CCI) has approved KKR's proposed acquisition of Healthcare Global Enterprises Limited, a specialist in oncology care. The purchase will be executed through KKR's entities Hector Asia Holdings and KIA EBT II Scheme. This approval is a crucial step in KKR's expansion strategy in the Indian healthcare market, subject to additional regulatory approvals and closing conditions. While financial details are undisclosed, the acquisition could bring global expertise and capital to Healthcare Global Enterprises, potentially impacting India's healthcare industry landscape.
24Feb 25
KKR to Acquire Controlling Stake in HealthCare Global Enterprises for ₹3,428 Crore
Global investment firm KKR is set to acquire a controlling stake of up to 54% in HealthCare Global Enterprises Ltd (HCG), India's largest cancer care provider, for ₹3,428 crore ($400 million). The deal involves a two-tranche acquisition at ₹445 per share, with an open offer to public shareholders at ₹504.41 per share. HCG's founder, Dr. BS Ajaikumar, will transition to Non-Executive Chairman. The transaction, expected to close by Q3 2025, is subject to regulatory approvals and aims to support the development of medical infrastructure and oncology services in India.
1 Year Returns:+42.55%
Industry Peers
Max Healthcare Institute
1,095.70
(+1.09%)
Apollo Hospitals
7,186.00
(-0.21%)
Fortis Healthcare
890.50
(+0.22%)
Narayana Hrudayalaya
1,917.30
(-1.05%)
Aster DM Healthcare
634.00
(-2.95%)
Global Health
1,159.90
(-3.41%)